secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001178913-22-001915
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q1 net loss $3.8M ($0.13/shr); cash $20.1M, expects funding into Q4 2022
--------------------------------------------------------------------------------

- Revenue $68K from Amgen R&D services, down from $157K YoY; operating expenses $3.8M vs $2.4M.
- Cash $20.1M at March 31, 2022 (vs $24.9M Dec 31); expects to fund operations into Q4 2022.
- EB613 (oral PTH for osteoporosis): FDA completed CMC review; Phase 3 trial design underway.
- Market study: >15M U.S. osteoporosis patients, 75% untreated; clinicians favor oral anabolic.
- EB612 hypoparathyroidism: orphan drug status; working on improved formulation for next trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/0001178913-22-001915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-001915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer